 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study. The pivotal trial is investigating tabelecleucel tab-cel for the treatment of Epstein-Barr virus-positive po 